205 related articles for article (PubMed ID: 26936942)
21. Menopause.
Nelson HD
Lancet; 2008 Mar; 371(9614):760-70. PubMed ID: 18313505
[TBL] [Abstract][Full Text] [Related]
22. NAMS releases position statement on the treatment of vasomotor symptoms associated with menopause.
Neff MJ
Am Fam Physician; 2004 Jul; 70(2):393-4, 396, 399. PubMed ID: 15291096
[TBL] [Abstract][Full Text] [Related]
23. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
Kenemans P; Speroff L;
Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
[TBL] [Abstract][Full Text] [Related]
24. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
Pinkerton JV; Pickar JH; Racketa J; Mirkin S
Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms.
Speroff L; Haney AF; Gilbert RD; Ellman H;
Menopause; 2006; 13(3):442-50. PubMed ID: 16735941
[TBL] [Abstract][Full Text] [Related]
26. Perspective on menopausal vasomotor symptoms, CAM, and the SWAN.
Pinkerton JV; Pastore LM
Menopause; 2007; 14(4):601-5. PubMed ID: 17529901
[No Abstract] [Full Text] [Related]
27. Spanish Menopause Society position statement: use of tibolone in postmenopausal women.
Mendoza N; Abad P; Baró F; Cancelo MJ; Llaneza P; Manubens M; Quereda F; Sánchez-Borrego R
Menopause; 2013 Jul; 20(7):754-60. PubMed ID: 23793166
[TBL] [Abstract][Full Text] [Related]
28. Hormone therapy for the management of menopausal symptoms: pharmacotherapy update.
Woodis CB
J Pharm Pract; 2010 Dec; 23(6):540-7. PubMed ID: 21507860
[TBL] [Abstract][Full Text] [Related]
29. Hormonal and nonhormonal treatment of vasomotor symptoms.
Krause MS; Nakajima ST
Obstet Gynecol Clin North Am; 2015 Mar; 42(1):163-79. PubMed ID: 25681847
[TBL] [Abstract][Full Text] [Related]
30. Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women.
Worsley R; Bell RJ; Gartoulla P; Davis SR
Menopause; 2016 Jan; 23(1):11-7. PubMed ID: 26240945
[TBL] [Abstract][Full Text] [Related]
31. Nonhormone therapies for vasomotor symptom management.
Iyer TK; Fiffick AN; Batur P
Cleve Clin J Med; 2024 Apr; 91(4):237-244. PubMed ID: 38561208
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the evidence for over-the-counter alternatives for relief of hot flashes in menopausal women.
Kelley KW; Carroll DG
J Am Pharm Assoc (2003); 2010; 50(5):e106-15. PubMed ID: 20833608
[TBL] [Abstract][Full Text] [Related]
33. Oestrogen replacement in postmenopausal women.
Sassarini J; Lumsden MA
Age Ageing; 2015 Jul; 44(4):551-8. PubMed ID: 26070875
[TBL] [Abstract][Full Text] [Related]
34. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS).
Glaser R; York AE; Dimitrakakis C
Maturitas; 2011 Apr; 68(4):355-61. PubMed ID: 21177051
[TBL] [Abstract][Full Text] [Related]
35. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
Komm BS; Mirkin S; Jenkins SN
Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
[TBL] [Abstract][Full Text] [Related]
36. A review of paroxetine for the treatment of vasomotor symptoms.
Slaton RM; Champion MN; Palmore KB
J Pharm Pract; 2015 Jun; 28(3):266-74. PubMed ID: 25107421
[TBL] [Abstract][Full Text] [Related]
37. Menopausal hot flushes and night sweats: where are we now?
Archer DF; Sturdee DW; Baber R; de Villiers TJ; Pines A; Freedman RR; Gompel A; Hickey M; Hunter MS; Lobo RA; Lumsden MA; MacLennan AH; Maki P; Palacios S; Shah D; Villaseca P; Warren M
Climacteric; 2011 Oct; 14(5):515-28. PubMed ID: 21848495
[TBL] [Abstract][Full Text] [Related]
38. Clinical practice. Management of menopausal symptoms.
Grady D
N Engl J Med; 2006 Nov; 355(22):2338-47. PubMed ID: 17135587
[No Abstract] [Full Text] [Related]
39. [Clinical practice guideline. Diagnosis and treatment of postmenopausal and perinemopausia].
Alvarado-García A; Hernández-Quijano T; Hernández-Valencia M; Negrín-Pérez MC; Ríos-Castillo B; Valencia-Pérez GU; Vital-Reyes VS; Basavilvazo-Rodríguez MA; Torres-Arreola LP; Ortiz-Luna GF; Sánchez-Aguirre F; Montaño-Uscanga A
Rev Med Inst Mex Seguro Soc; 2015; 53(2):214-25. PubMed ID: 25760751
[TBL] [Abstract][Full Text] [Related]
40. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
